For example, increased levels of FABP1 were reported in the early stage of gastric cancers, with a specificity of 95%, and in the advanced stage of cancer recurrence with a sensitivity of 67%, demonstrating a potential biomarker for the worse prognosis 43. Here, FABP1 is linked to cancer.